BioDrugs

, Volume 25, Issue 2, pp 89–103

Tacrolimus in the Treatment of Ocular Diseases

Review Article

Abstract

Tacrolimus (FK506) has been used successfully as a systemic immunomodulator for more than 2 decades, and numerous studies have investigated its mechanisms of action. Systemic and topical tacrolimus have been investigated as treatments for ocular surface disorders that may have an immune-based inflammatory component. In these studies, tacrolimus has shown efficacy in corneal graft rejection, inflammatory conjunctival and corneal diseases, uveitis, and graft-versus-host disease. As these disorders are often refractory to other available treatments, ophthalmic or systemic tacrolimus is a welcome nontoxic adjunct or replacement to potentially toxic topical or systemic immunosuppressive therapies.

References

  1. 1.
    Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces: I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot 1987; 40: 1249–55PubMedCrossRefGoogle Scholar
  2. 2.
    Jensik SC. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group. Transplant Proc 1998; 30(4): 1216–8PubMedCrossRefGoogle Scholar
  3. 3.
    O’Grady JG, Burroughs A, Hardy P, et al. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet 2002; 360: 1119–25PubMedCrossRefGoogle Scholar
  4. 4.
    Griffith BP, Bando K, Hardesty RL, et al. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. Transplantation 1994; 57(6): 848–51PubMedCrossRefGoogle Scholar
  5. 5.
    Ligtenberg G, Hene RJ, Blankestijn PJ, et al. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001; 12(2): 368–73PubMedGoogle Scholar
  6. 6.
    Textor SC, Wiesner R, Wilson DJ, et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 1993; 55: 1332–9PubMedCrossRefGoogle Scholar
  7. 7.
    Friemann S, Feuring E, Padberg W, et al. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. Transplant Proc 1998; 30: 1240–2PubMedCrossRefGoogle Scholar
  8. 8.
    Nakagawa H, Etoh T, Ishibashi Y, et al. Tacrolimus ointment for atopic dermatitis [letter]. Lancet 1994; 344(8926): 883PubMedCrossRefGoogle Scholar
  9. 9.
    Aoyama H, Tabata N, Tanaka M, et al. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. Br J Dermatol 1995; 133: 494–6PubMedCrossRefGoogle Scholar
  10. 10.
    Ruzicka T, Bieber T, Schöpf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997; 337: 816–21PubMedCrossRefGoogle Scholar
  11. 11.
    Mandelin J, Remitz A, Virtanen H, et al. One-year treatment with 0.1 % tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: a randomized, double-blind, comparative trial. Acta Derm Venereol 2010 Mar; 90(2): 170–4PubMedCrossRefGoogle Scholar
  12. 12.
    Kobayashi C, Kanai A, Nakajima A, et al. Suppression of corneal graft rejection in rabbits by a new immunosuppressive agent, FK-506. Transplant Proc 1989; 21 (1Pt 3): 3156–8PubMedGoogle Scholar
  13. 13.
    Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology 2001; 108(10): 1838–44PubMedCrossRefGoogle Scholar
  14. 14.
    Joseph A, Raj D, Shanmuganathan V, et al. Tacrolimus immunosuppression in high-risk corneal grafts. Br J Ophthalmol 2007; 91(1): 51–5PubMedCrossRefGoogle Scholar
  15. 15.
    Astellas Pharma Inc. Phase III study of 0.1% tacrolimus (FK506) ophthalmic suspension in patients with vernal keratoconjunctivitis [ClinicalTrials.gov identifier NCT00567762]. US National Institutes of Health, Clinical-Trials. gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jan 30]
  16. 16.
    Tam PM, Young AL, Cheng LL, et al. Topical 0.03% tacrolimus ointment in the management of ocular surface inflammation in chronic GVHD. Bone Marrow Transplant 2009; 45(5): 957–8PubMedCrossRefGoogle Scholar
  17. 17.
    Suresh L, Martinez Calixto LE, Radfar L. Successful treatment of mucous membrane pemphigoid with tacrolimus. Spec Care Dentist 2006; 26(2): 66–70PubMedCrossRefGoogle Scholar
  18. 18.
    Ishioka M, Ohno S, Nakamura S, et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol 1994; 118(6): 723–9PubMedGoogle Scholar
  19. 19.
    Mochizuki M, Masuda K, Sakane T, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 1993; 115(6): 763–9PubMedGoogle Scholar
  20. 20.
    Mochizuki M, Ikeda E, Shirao M, et al. Preclinical and clinical study of FK506 in uveitis. Curr Eye Res 1992; 11 Suppl.: 87–95PubMedCrossRefGoogle Scholar
  21. 21.
    Okada K, Sakata H, Minamoto A, et al. Effect of FK 506 administered topically versus intramuscularly on suppression of the corneal immune reaction in rats. Int J Ophthalmol 1996; 210(3): 175–9CrossRefGoogle Scholar
  22. 22.
    Hikita N, Lopez JS, Chan CC, et al. Use of topical FK506 in a corneal graft rejection model in Lewis rats. Invest Ophthalmol Vis Sci 1997; 38(5): 901–9PubMedGoogle Scholar
  23. 23.
    Fei WL, Chen JQ, Yuan J, et al. Preliminary study of the effect of FK506 nanospheric-suspension eyedrops on rejection of penetrating keratoplasty. J Ocul Pharmacol Ther 2008; 24(2): 235–44PubMedCrossRefGoogle Scholar
  24. 24.
    Dhaliwal JS, Mason BF, Kaufman SC. Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty. Cornea 2008; 27(4): 488–93PubMedCrossRefGoogle Scholar
  25. 25.
    Liang L, Sheha H, Tseng SCG. Long-term outcomes of keratolimbal allograft for total limbal stem cell deficiency using combined immunosuppressive agents and correction of ocular surface deficits. Arch Ophthalmol 2009; 127(11): 1428–34PubMedCrossRefGoogle Scholar
  26. 26.
    Vichyanond P, Tantimongkolsuk C, Dumrongkigchaiporn P, et al. Vernal keratoconjunctivitis: result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment. J Allergy Clin Immunol 2004; 113(2): 355–8PubMedCrossRefGoogle Scholar
  27. 27.
    Fei WL, Chen JQ, Wang ZC, et al. Treatment of severe vernal kerato-conjunctivitis with topical FK506. Chin J Pract Ophthalmol 2004; 22: 916–8Google Scholar
  28. 28.
    Ohashi Y, Ebihara N, Fujishima H, et al. A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. J Ocul Pharmacol Ther 2010; 26(2): 165–74PubMedCrossRefGoogle Scholar
  29. 29.
    Rikkers SM, Holland GN, Drayton GE, et al. Topical tacrolimus treatment of atopic eyelid disease. Am J Ophthalmol 2003; 135(3): 297–302PubMedCrossRefGoogle Scholar
  30. 30.
    Nivenius E, van der Ploeg I, Jung K, et al. Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis. Eye 2007; 21(7): 968–75PubMedCrossRefGoogle Scholar
  31. 31.
    Zribi H, Descamps V, Hoang-Xuan T, et al. Dramatic improvement of atopic keratoconjunctivitis after topical treatment with tacrolimus ointment restricted to the eyelids. J Eur Acad Dermatol Venereol 2009; 23(4): 489–90PubMedCrossRefGoogle Scholar
  32. 32.
    Virtanen HM, Reitamo S, Kari M, et al. Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study. Acta Ophthalmol Scand 2006; 84(5): 693–5PubMedCrossRefGoogle Scholar
  33. 33.
    Attas-Fox L, Barkana Y, Iskhakov V, et al. Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study. Curr Eye Res 2008; 33(7): 545–9PubMedCrossRefGoogle Scholar
  34. 34.
    Xie H, Chen J, Lin Y, et al. Effect of topical FK506 used alone or combined with keratoplasty on patients with recurrent Mooren’s corneal ulcer. Yan Ke Xue Bao 2006; 22: 207–13PubMedGoogle Scholar
  35. 35.
    Sakurai E, Nozaki M, Okabe K, et al. Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis. Invest Ophthalmol Vis Sci 2003; 44: 4845–52PubMedCrossRefGoogle Scholar
  36. 36.
    Oh-i K, Keino H, Goto H, et al. Upregulation of neurotrophic factor-related gene expression in retina with experimental autoimmune uveoretinitis by intravitreal injection of tacrolimus (FK506). Br J Ophthalmol 2007; 91: 1537–40PubMedCrossRefGoogle Scholar
  37. 37.
    Oh-i K, Keino H, Goto H, et al. Intravitreal injection of tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoretinitis in rats. Br J Ophthalmol 2007; 91: 237–42PubMedCrossRefGoogle Scholar
  38. 38.
    Fujino Y, Mochizuki M, Chan CC, et al. FK506 treatment of S-antigen induced uveitis in primates. Curr Eye Res 1991; 10(7): 679–90PubMedCrossRefGoogle Scholar
  39. 39.
    Hogan AC, McAvoy CE, Dick AD, et al. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 2007; 114(5): 1000–6PubMedCrossRefGoogle Scholar
  40. 40.
    Tichelli A, Duell T, Weiss M, et al. Late-onset keratoconjunctivitis sicca syndrome after bone marrow transplantation: incidence and risk factors. European Group or Blood and Marrow Transplantation (EBMT) Working Party on Late Effects. Bone Marrow Transplant 1996; 17(6): 1105–11PubMedGoogle Scholar
  41. 41.
    Kerty E, Vigander K, Flage T, et al. Ocular findings in allogenic stem cell transplantation without total body irradiation. Ophthalmology 1999; 106: 1334–8PubMedCrossRefGoogle Scholar
  42. 42.
    Ogawa Y, Yamazaki K, Kuwana M, et al. A significant role of stromal fibroblasts in rapidly progressive dry eye in patients with chronic GVHD. Invest Ophthalmol Vis Sci 2001; 42(1): 111–9PubMedGoogle Scholar
  43. 43.
    Ahmad SM, Stegman Z, Fructhman S, et al. Successful treatment of acute ocular graft-versus-host disease with tacrolimus (FK506). Cornea 2002; 21(4): 432–3PubMedCrossRefGoogle Scholar
  44. 44.
    Lawrence ID. Tacrolimus (FK506): experience in dermatology. Dermatologic Ther 1998; 5: 74–84Google Scholar
  45. 45.
    Harding MW, Galat A, Uehling DE, et al. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989; 341: 758–60PubMedCrossRefGoogle Scholar
  46. 46.
    Siekierka JJ, Hung SHY, Poe M, et al. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 1989; 341: 755–7PubMedCrossRefGoogle Scholar
  47. 47.
    Shaw KTY, Ho AM, Raghavan A, et al. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT 1 in stimulated immune cells. Proc Natl Acad Sci U S A 1995; 92: 11205–9PubMedCrossRefGoogle Scholar
  48. 48.
    Ruff VA, Leach KL. Direct demonstration of NFATp dephosphorylation and nuclear localization in activated HT-2 cells using a specific NFATp polyclonal antibody. J Biol Chem 1995; 270: 22602–7PubMedCrossRefGoogle Scholar
  49. 49.
    Tamura K, Fujimura T, Iwasaki K, et al. Interaction of tacrolimus (FK506) and its metabolites with FKBP and calcineurin. Biochem Biophys Res Commun 1994; 202(1): 437–43PubMedCrossRefGoogle Scholar
  50. 50.
    Liu J, Farmer J, Lane W, et al. Calcineurin is a common target of cyclophilincyclosporin A and FKBP-FK506 complexes. Cell 1991; 66(4): 807–15PubMedCrossRefGoogle Scholar
  51. 51.
    Ruzicka T, Assmann T, Homey B. Tacrolimus: the drug for the turn of the millennium? Arch Dermatol 1999; 135(5): 574–80PubMedCrossRefGoogle Scholar
  52. 52.
    de Paulis A, Stellato C, Cirillo R, et al. Antiinflammatory effects of FK506 on human skin mast cells. J Invest Dermatol 1992; 99: 723–8PubMedCrossRefGoogle Scholar
  53. 53.
    Busuttil RW, Holt CD. Tacrolimus is superior to cyclosporine in liver transplantation. Transplant Proc 1998; 30(5): 2174–8PubMedCrossRefGoogle Scholar
  54. 54.
    Cao S, Cox KL, Berquist W, et al. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus. Pediatr Transplant 1999; 3(1): 22–6PubMedCrossRefGoogle Scholar
  55. 55.
    McDiarmid SV. The use of tacrolimus in pediatric liver transplantation. J Pediatr Gastroenterol Nutr 1998; 26(1): 90–102PubMedCrossRefGoogle Scholar
  56. 56.
    Reyes J, Jain A, Mazariegos G, et al. Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. Transplantation 2000; 69(12): 2573–80PubMedCrossRefGoogle Scholar
  57. 57.
    Berloco P, Rossi M, Pretagostini R, et al. Tacrolimus as cornerstone immunosuppressant in kidney transplantation. Transplant Proc 2001; 33(1-2): 994–6PubMedCrossRefGoogle Scholar
  58. 58.
    Laskow DA, Neylan 3rd JF, Shapiro RS, et al. The role of tacrolimus in adult kidney transplantation: a review. Clin Transplant 1998; 12(6): 489–503PubMedGoogle Scholar
  59. 59.
    Shapiro R. Tacrolimus in solid organ transplantation: an update. Transplant Proc 1999; 31(6): 2203–5PubMedCrossRefGoogle Scholar
  60. 60.
    Shapiro R. Tacrolimus in pediatric renal transplantation: a review. Pediatr Transplant 1998; 2(4): 270–6PubMedGoogle Scholar
  61. 61.
    Pham SM, Kormos RL, Kawai A, et al. Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience. Transplant Proc 1996; 28(2): 1002–4PubMedGoogle Scholar
  62. 62.
    De Bonis M, Reynolds L, Barros J, et al. Tacrolimus as a rescue immunosuppressant after heart transplantation. Eur J Cardiothorac Surg 2001; 19(5): 695–9Google Scholar
  63. 63.
    Crespo-Leiro MG, Paniagua MJ, Mosquera I, et al. Replacement of cyclosporine by tacrolimus for immunosuppression in heart transplant patients: safety and efficacy. Transplant Proc 2002; 34(1): 113–4PubMedCrossRefGoogle Scholar
  64. 64.
    Swenson JM, Fricker FJ, Armitage JM. Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK506. J Am Coll Cardiol 1995; 25(5): 1183–8PubMedCrossRefGoogle Scholar
  65. 65.
    Reyes J, Mazariegos GV, Bond GM, et al. Pediatric intestinal transplantation: historical notes, principles and controversies. Pediatr Transplant 2002; 6(3): 193–207PubMedCrossRefGoogle Scholar
  66. 66.
    Kato T, Ruiz P, Thompson JF, et al. Intestinal and multivisceral transplantation. World J Surg 2002; 26(2): 226–37PubMedCrossRefGoogle Scholar
  67. 67.
    Jindal RM, Dubernard JM. Towards a specific immunosuppression for pancreas and islet grafts. Clin Transplant 2000; 14(3): 242–5PubMedCrossRefGoogle Scholar
  68. 68.
    Stratta RJ. Optimal immunosuppression in pancreas transplantation. Transplant Proc 1999; 31(1-2): 619–21PubMedCrossRefGoogle Scholar
  69. 69.
    Stratta RJ, Taylor RJ, Castaldo P, et al. FK 506 induction and rescue therapy in pancreas transplant recipients. Transplant Proc 1996; 28(2): 991–2PubMedGoogle Scholar
  70. 70.
    Gruessner RW. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Clin Transplant 1997; 11(4): 299–312PubMedGoogle Scholar
  71. 71.
    Jordan ML, Shapiro R, Gritsch HA, et al. Long-term results of pancreas transplantation under tacrolimus immunosuppression. Transplantation 1999; 67(2): 266–72PubMedCrossRefGoogle Scholar
  72. 72.
    Horning NR, Lynch JP, Sundaresan SR, et al. Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. J Heart Lung Transplant 1998; 17(8): 761–7PubMedGoogle Scholar
  73. 73.
    Kur F, Reichenspurner H, Meiser BM, et al. Tacrolimus (FK506) as primary immunosuppressant after lung transplantation. Thorac Cardiovasc Surg 1999; 47(3): 174–8PubMedCrossRefGoogle Scholar
  74. 74.
    Lipson DA, Palevsky HI, Kotloff RM, et al. Conversion to tacrolimus (FK506) from cyclosporine after orthotopic lung transplantation. Transplant Proc 1998; 30(4): 1505–7PubMedCrossRefGoogle Scholar
  75. 75.
    Reichenspurner H, Kur F, Treede H, et al. Optimization of the immunosuppressive protocol after lung transplantation. Transplantation 1999; 68(1): 67–71PubMedCrossRefGoogle Scholar
  76. 76.
    Treede H, Klepetko W, Reichenspurner H, et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized twocenter trial comparing two different immunosuppressive protocols. J Heart Lung Transplant 2001; 20(5): 511–7PubMedCrossRefGoogle Scholar
  77. 77.
    Schrepfer S, Deuse T, Reichenspurner H, et al. Effect of inhaled tacrolimus on cellular and humoral rejection to prevent posttransplant obliterative airway disease. Am J Transplant 2007; 7(7): 1733–42PubMedCrossRefGoogle Scholar
  78. 78.
    Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92(7): 2303–14PubMedGoogle Scholar
  79. 79.
    Fay JW, Wingard JR, Antin JH, et al. FK506 (tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. Blood 1996; 87(8): 3514–9PubMedGoogle Scholar
  80. 80.
    Jacobson P, Uberti J, Davis W, et al. Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. Bone Marrow Transplant 1998; 22(3): 217–25PubMedCrossRefGoogle Scholar
  81. 81.
    Lee TJ, Kennedy LA. Tacrolimus: an alternative for graft-versus-host disease prevention. Ann Pharmacother 2000; 34(3): 377–81PubMedCrossRefGoogle Scholar
  82. 82.
    Yanik G, Levine JE, Ratanatharathorn V, et al. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation. Bone Marrow Transplant 2000; 26(2): 161–7PubMedCrossRefGoogle Scholar
  83. 83.
    Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29(6): 404–30PubMedCrossRefGoogle Scholar
  84. 84.
    Tacrolimus (Prograf) [prescribing information]. Deerfield (IL): Fujisawa Healthcare Inc., 2003 Aug [online]. Available from URL: http://www.fujisawa.com/medinfo/pi/pi_main_pg.htm [Accessed 2011 Jan 30]
  85. 85.
    Jain AB, Venkataramanan R, Cadoff E, et al. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc 1990; 22(1): 57–9PubMedGoogle Scholar
  86. 86.
    McMaster P, Mirza DF, Ismail T, et al. Therapeutic drug monitoring of tacrolimus in clinical transplantation. Ther Drug Monit 1995; 17(6): 602–5PubMedCrossRefGoogle Scholar
  87. 87.
    Christians U, Jacobsen W, Benet LZ, et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41(11): 813–51PubMedCrossRefGoogle Scholar
  88. 88.
    Bekersky I, Dressler D, Alak A, et al. Comparative tacrolimus pharmacokinetics: normal versus mildly hepatically impaired subjects. J Clin Pharmacol 2001; 41(6): 628–35PubMedCrossRefGoogle Scholar
  89. 89.
    Suzuki K, Saito K, Tsujimura S, et al. Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis. J Rheumatol 2010; 37(3): 512–20PubMedCrossRefGoogle Scholar
  90. 90.
    Aramaki T, Kawakami A, Iwamoto N, et al. Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables. Mod Rheumatol 2009; 19(6): 652–6PubMedCrossRefGoogle Scholar
  91. 91.
    Kawachi Y, Nakamura Y, Yoh K, et al. Rheumatoid papules successfully treated with oral tacrolimus. J Eur Acad Dermatol Venereol 2008; 22(2): 241–2PubMedGoogle Scholar
  92. 92.
    Kalb RE, Bagel J, Korman NJ, et al. Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009; 60(1): 120–4PubMedCrossRefGoogle Scholar
  93. 93.
    Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61(3): 451–85PubMedCrossRefGoogle Scholar
  94. 94.
    Matsumura K, Nakase H, Chiba T. Efficacy of oral tacrolimus on intestinal Behcet’s disease. Inflamm Bowel Dis 2010; 16(2): 188–9PubMedCrossRefGoogle Scholar
  95. 95.
    Schwartz M, Cohen R. Optimizing conventional therapy for inflammatory bowel disease. Curr Gastroenterol Rep 2008; 10(6): 585–90PubMedCrossRefGoogle Scholar
  96. 96.
    Dignass AU, Hartmann F, Sturm A, et al. Management of inflammatory bowel diseases during pregnancy. Dig Dis 2009; 27(3): 341–6PubMedCrossRefGoogle Scholar
  97. 97.
    Moscandrew M, Kane S. Inflammatory bowel diseases and management considerations: fertility and pregnancy. Curr Gastroenterol Rep 2009; 11(5): 395–9PubMedCrossRefGoogle Scholar
  98. 98.
    Yalcindag FN, Incel O, Ozdemir O. Effectiveness of tacrolimus in high-risk limbal allo-graft transplantation. Ann Ophthalmol (Skokie) 2008; 40(3-4): 152–6Google Scholar
  99. 99.
    Kulkarni P. Uveitis and immunosuppressive drugs. J Ocul Pharmacol Ther 2001; 17(2): 181–7PubMedCrossRefGoogle Scholar
  100. 100.
    Jap A, Chee S-P. Immunosuppressive therapy for ocular diseases. Curr Opin Ophthalmol 2008; 19(6): 535–40PubMedCrossRefGoogle Scholar
  101. 101.
    Yalçindağ FN, Batioğlu F, Ozdemir O. Penetration of topically applied tacrolimus into the aqueous humor in Behçet’s disease. Ann Ophthalmol (Skokie) 2007; 39(1): 15–7CrossRefGoogle Scholar
  102. 102.
    Lin P, Liang G. Behcet disease: recommendation for clinical management of mucocutaneous lesions. J Clin Rheumatol 2006; 12(6): 282–6PubMedCrossRefGoogle Scholar
  103. 103.
    Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol 2005; 50(4): 297–350PubMedCrossRefGoogle Scholar
  104. 104.
    Uno T, Yamaguchi T, Li XK, et al. The pharmacokinetics of water-in-oil-in-water-type multiple emulsion of a new tacrolimus formulation. Lipids 1997; 32(5): 543–8PubMedCrossRefGoogle Scholar
  105. 105.
    Pleyer U, Lutz S, Juske WJ, et al. Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Invest Ophthalmol Vis Sci 1993; 34: 2737–42PubMedGoogle Scholar
  106. 106.
    Yura H, Yoshimura N, Hamashima T, et al. Synthesis and pharmacokinetics of a novel macromolecular prodrug of tacrolimus (FK506), FK506-dextran conjugate. J Control Release 1999; 57(1): 87–99PubMedCrossRefGoogle Scholar
  107. 107.
    Whitcup SM, Pleyer U, Lai JC, et al. Topical liposome-encapsulated FK506 for the treatment of endotoxin-induced uveitis. Ocul Immunol Inflam 1998; 6(1): 51–6CrossRefGoogle Scholar
  108. 108.
    Fujita E, Teramura Y, Mitsugi K, et al. Absorption, distribution, and excretion of 14C-labeled tacrolimus (FK506) after a single or repeated ocular instillation in rabbits. J Ocul Pharmacol Ther 2008; 24(3): 333–43PubMedCrossRefGoogle Scholar
  109. 109.
    Fujita E, Teramura Y, Shiraga T, et al. Pharmacokinetics and tissue distribution of tacrolimus (FK506) after a single or repeated ocular instillation in rabbits. J Ocul Pharmacol Ther 2008; 24(3): 309–19PubMedCrossRefGoogle Scholar
  110. 110.
    Fei WL, Chen JQ, Zhong SL, et al. The pharmacokinetics of FK506 and its nanoparticles in aqueous humor of rabbits. Zhonghua Yan Ke Za Zhi 2006; 42(4): 305–8PubMedGoogle Scholar
  111. 111.
    Yuan J, Zhai JJ, Chen JQ, et al. Preparation of 0.05% FK506 suspension eyedrops and its pharmacokinetics after topical ocular administration. J Ocul Pharmacol Ther 2009; 25(4): 345–50PubMedCrossRefGoogle Scholar
  112. 112.
    Starzl TE, Todo S, Fung J, et al. FK506 for liver, kidney, and pancreas transplantation. Lancet 1989; 2: 1000–4PubMedCrossRefGoogle Scholar
  113. 113.
    Yang P, Gong X, Zhou H, et al. Immunological studies on the cellular phenotype involved in corneal allograft rejection. Chin Med J (Engl) 1999; 112: 202–6PubMedGoogle Scholar
  114. 114.
    Metz DP, Bacon AS, Holgate S, et al. Phenotypic characterization of T cells infiltrating the conjunctiva in chronic allergic eye disease. J Allergy Clin Immunol 1996; 98(3): 686–96PubMedCrossRefGoogle Scholar
  115. 115.
    Maggi E, Biswas P, Del Prete G, et al. Accumulation of Th-2-like helper T cells in the conjunctiva of patients with vernal conjunctivitis. J Immunol 1991; 146(4): 1169–74PubMedGoogle Scholar
  116. 116.
    Metz DP, Hingorani M, Calder VL, et al. T-cell cytokines in chronic allergic eye disease. J Allergy Clin Immunol 1997; 100 (6 Pt 1): 817–24PubMedCrossRefGoogle Scholar
  117. 117.
    Leonardi A, DeFranchis G, Zancanaro F, et al. Identification of local Th2 and Th0 lymphocytes in vernal conjunctivitis by cytokine flow cytometry. Invest Ophthalmol Vis Sci 1999; 40(12): 3036–40PubMedGoogle Scholar
  118. 118.
    Leonardi A, Sathe S, Bortolotti M, et al. Cytokines, matrix metalloproteases, angiogenic and growth factors in tears of normal subjects and vernal keratoconjunctivitis patients. Allergy 2009; 64(5): 710–7PubMedCrossRefGoogle Scholar
  119. 119.
    Bielory L. Allergic and immunologic disorders of the eye: part II, ocular allergy. J Allerg Clin Immunol 2000; 106(6): 1019–32CrossRefGoogle Scholar
  120. 120.
    Bonini S, Lambiase A, Marchi S, et al. Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term follow-up. Ophthalmology 2000; 107: 1157–63PubMedCrossRefGoogle Scholar
  121. 121.
    Sengoku T, Sakuma S, Satoh S, et al. Effect of FK506 eyedrops on late and delayed-type responses in ocular allergy models. Clin Exp Allergy 2003; 33(11): 1555–60PubMedCrossRefGoogle Scholar
  122. 122.
    Butcher SP, Henshall DC, Teramura Y, et al. Neuroprotective actions of FK506 in experimental stroke: in vivo evidence against an antiexcitotoxic mechanism. J Neurosci 1997; 17: 6939–46PubMedGoogle Scholar
  123. 123.
    Furuichi Y, Noto T, Li JY, et al. Multiple modes of action of tacrolimus (FK506) for neuroprotective action on ischemic damage after transient focal cerebral ischemia in rats. Brain Res 2004; 1014: 120–30PubMedCrossRefGoogle Scholar
  124. 124.
    Labrande C, Velly L, Canolle B, et al. Neuroprotective effects of tacrolimus (FK506) in a model of ischemic cortical cell cultures: role of glutamate uptake and FK506 binding protein 12kDa. Neuroscience 2006; 137: 231–9PubMedCrossRefGoogle Scholar
  125. 125.
    Iwasaki Y, Ichikawa Y, Igarashi O, et al. Neuroprotective actions of FK506 and cyclosporin A on motor neuron survival following neonatal axotomy. Neurol Res 2002; 24: 573–6PubMedCrossRefGoogle Scholar
  126. 126.
    Hamrah P, Reza Dana M. Corneal antigen-presenting cells. Chem Immunol Allergy 2007; 92: 58–70PubMedCrossRefGoogle Scholar
  127. 127.
    Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381(6581): 434–8PubMedCrossRefGoogle Scholar
  128. 128.
    Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD 154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5(6): 686–93PubMedCrossRefGoogle Scholar
  129. 129.
    Iwata M, Soya K, Sawa M, et al. CD40 expression in normal human cornea and regulation of CD40 in cultured human corneal epithelial and stromal cells. Invest Ophthalmol Vis Sci 2002; 43(2): 348–57PubMedGoogle Scholar
  130. 130.
    Bourcier T, De Saint-Jean M, Brignole F, et al. Expression of CD40 and CD40 ligand in the human conjunctival epithelium. Invest Ophthalmol Vis Sci 2000; 41(1): 120–6PubMedGoogle Scholar
  131. 131.
    Brignole F, Pisella PJ, Goldschild M, et al. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Invest Ophthalmol Vis Sci 2000; 41(6): 1356–63PubMedGoogle Scholar
  132. 132.
    Qian Y, Dana MR. Effect of locally administered anti-CD154 (CD40 ligand) monoclonal antibody on survival of allogeneic corneal transplants. Cornea 2002; 21: 592–7PubMedCrossRefGoogle Scholar
  133. 133.
    Loser K, Balkow S, Higuchi T, et al. FK506 controls CD40L-induced systemic autoimmunity in mice. J Invest Dermatol 2006; 126(6): 1307–15PubMedCrossRefGoogle Scholar
  134. 134.
    Niederkorn JY. The immune privilege of corneal allografts. Transplantation 1999; 67(12): 1503–8PubMedCrossRefGoogle Scholar
  135. 135.
    Williams KA, Muehlberg SM, Lewis RF, et al. How successful is corneal transplantation? A report from the Australian corneal graft register. Eye 1995; 9: 219–27PubMedCrossRefGoogle Scholar
  136. 136.
    Stark W, Stulting D, Mauguire M, et al. The collaborative corneal transplantation studies (CCTS): effectiveness of histocompatibility matching of donors and recipients in high-risk corneal transplantation. Arch Ophthalmol 1992; 110: 1392–403CrossRefGoogle Scholar
  137. 137.
    Council of Scientific Affairs. Report of the organ transplant panel: corneal transplantation. JAMA 1988; 259: 719–22CrossRefGoogle Scholar
  138. 138.
    Kuffova L, Vesela V, Filipec M, et al. Cell subpopulation in failed human corneal grafts. Br J Ophthalmol 1999; 83: 1364–9PubMedCrossRefGoogle Scholar
  139. 139.
    Gebhardt BM, Shi W. Experimental corneal allograft rejection. Immunol Res 2002; 25(1): 1–26PubMedCrossRefGoogle Scholar
  140. 140.
    Sangwan VS, Ramamurthy B, Shah U, et al. Outcome of corneal transplant rejection: a 10-year study. Clin Exp Ophthalmol 2005; 33(6): 623–7CrossRefGoogle Scholar
  141. 141.
    Tabbara KF. Pharmacologic strategies in the prevention and treatment of corneal transplant rejection. Int Ophthalmol 2008; 28(3): 223–32PubMedCrossRefGoogle Scholar
  142. 142.
    Benelli U, Lepri A, Del Tacca M, et al. FK-506 delays corneal graft rejection in a model of corneal xenotransplantation. J Ocul Pharmacol Ther 1996; 12(4): 425–31PubMedCrossRefGoogle Scholar
  143. 143.
    Tchah H, Lim B. Effect of FK 506 on the cornea: use of topical FK 506 in corneal transplantation in a guinea pig-rat model. Korean J Ophthalmol: KJO 1999; 13(2): 71–7PubMedGoogle Scholar
  144. 144.
    Holland EJ. Epithelial transplantation for the management of severe ocular surface disease. Trans Am Ophthalmol Soc 1996; 94: 677–743PubMedGoogle Scholar
  145. 145.
    Hill JC. Systemic cyclosporine in high-risk keratoplasty: short-versus longterm therapy. Ophthalmology 1994; 101: 128–33PubMedGoogle Scholar
  146. 146.
    Tsubota K, Satake Y, Kaido M, et al. Treatment of severe ocular surface disorders with corneal epithelial stem-cell transplantation. N Engl J Med 1999; 340: 1697–703PubMedCrossRefGoogle Scholar
  147. 147.
    Tabbara KF. Ocular complications of vernal keratoconjunctivitis. Can J Ophthalmol 1999; 34(2): 88–92PubMedGoogle Scholar
  148. 148.
    Kumar S. Vernal keratoconjunctivitis: a major review. Act Ophthalmol 2009; 87(2): 133–47CrossRefGoogle Scholar
  149. 149.
    Leonardi A. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog Retin Eye Res 2002; 21(3): 319–39PubMedCrossRefGoogle Scholar
  150. 150.
    Tam PM, Young AL, Cheng LL, et al. Topical tacrolimus 0.03% monotherapy for vernal keratoconjunctivitis: case series. Br J Ophthalmol 2010 Oct; 94(10): 1405–6PubMedCrossRefGoogle Scholar
  151. 151.
    Pepose JS, Holland GN, Wilhelmus KR, editors. Ocular infection and immunity. Philadelphia (PA): Mosby-Year Book, 1996: 376–90Google Scholar
  152. 152.
    Foster CS, Rice BA, Dutt JE. Immunopathology of atopic keratoconjunctivitis. Ophthalmology 1991; 98(8): 1190–6PubMedGoogle Scholar
  153. 153.
    Nivenius E, Montan PG, Chryssanthou E, et al. No apparent association between periocular and ocular microcolonization and the degree of inflammation in patients with atopic keratoconjunctivitis. Clin Exp Allergy 2004; 34(5): 725–30PubMedCrossRefGoogle Scholar
  154. 154.
    Berknowitz PJ, Arentsen JJ, Felberg NT. Presence of circulating immune complex in patients with corneal disease. Arch Ophthalmol 1983; 101: 242–5CrossRefGoogle Scholar
  155. 155.
    Lopez JS, Price Jr FW, Whitcup SM, et al. Immunohistochemistry of Terrien’s and Mooren’s corneal degeneration. Arch Ophthalmol 1991; 109: 988–92PubMedCrossRefGoogle Scholar
  156. 156.
    Gottsch JD, Liu SH, Minkovitz JB, et al. Autoimmunity to a cornea-associated stromal antigen in patients with Mooren’s ulcer. Invest Ophthalmol Vis Sci 1995; 30: 1541–7Google Scholar
  157. 157.
    Chen J, Xie H, Wang Z, et al. Mooren’s ulcer in China: a study of clinical characteristics and treatment. Br J Ophthalmol 2000; 84(11): 1244–9PubMedCrossRefGoogle Scholar
  158. 158.
    Nussenblatt RB, Palestine AG, Chan CC. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 1983; 96(3): 275–82PubMedGoogle Scholar
  159. 159.
    Ohia EO, Mancino M, Kulkarni PS. Effects of steroids and immunosuppressive drugs on endotoxin-uveitis in rabbits. J Ocul Pharmacol 1992; 8(4): 295–307PubMedCrossRefGoogle Scholar
  160. 160.
    Nussenblatt RB. The expanding use of immunosuppression in the treatment of noninfectious ocular disease. J Autoimmun 1992; 5: 247–57PubMedCrossRefGoogle Scholar
  161. 161.
    Wacker WB, Donoso LA, Kaslow CM, et al. Experimental allergic uveitis: isolation, characterization of localization of a soluble uveopathogenic antigen from bovine retina. J Immunol 1977; 119: 1949–58PubMedGoogle Scholar
  162. 162.
    Ishikawa T, Hokama H, Katagiri Y, et al. Effects of intravitreal injection of tacrolimus (FK506) in experimental uveitis. Curr Eye Res 2005; 30: 93–101PubMedCrossRefGoogle Scholar
  163. 163.
    Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 2005; 123: 634–41PubMedCrossRefGoogle Scholar
  164. 164.
    Ogawa Y, Masataka K. Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation. Cornea 2003; 22(7 Suppl.): S19–27PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  1. 1.State Key Laboratory of OphthalmologyZhongshan Ophthalmic Center, Sun Yat-sen UniversityGuangzhouChina
  2. 2.Institute of Ophthalmology and Visual Sciences of Guangdong ProvinceGuangzhouChina

Personalised recommendations